Literature DB >> 9430680

The R1 subunit of herpes simplex virus ribonucleotide reductase is a good substrate for host cell protein kinases but is not itself a protein kinase.

Y Langelier1, L Champoux, M Hamel, C Guilbault, N Lamarche, P Gaudreau, B Massie.   

Abstract

The N terminus of the R1 subunit of herpes simplex virus type 2 ribonucleotide reductase is believed to be a protein kinase domain mainly because the R1 protein was phosphorylated in a protein kinase assay on blot. Using Escherichia coli and adenovirus expression vectors to produce R1, we found that, whereas the reductase activity of both recombinant proteins was similar, efficient phosphorylation of R1 and casein in the presence of Mg2+ was obtained only with the R1 purified from eukaryotic cells. Phosphorylation of this R1, in solution or on blot, results mainly from the activity of casein kinase II (CKII), a co-purifying protein kinase. Labeling on blot occurs from CKII leakage off the membrane and its subsequent high affinity binding to in vivo CKII-phosphorylated R1. CKII target sites were mapped to an acidic serine-rich segment of the R1 N terminus. Improvement in purification of the R1 expressed in eukaryotic cells nearly completely abolished its phosphorylation potential. An extremely low level of phosphorylation observed in the presence of Mn2+ with the R1 produced in E. coli was probably due to an unidentified prokaryotic protein kinase. These results provide evidence that the herpes simplex virus type 2 R1 does not possess an intrinsic protein kinase activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9430680     DOI: 10.1074/jbc.273.3.1435

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

Review 1.  Viral serine/threonine protein kinases.

Authors:  Thary Jacob; Céline Van den Broeke; Herman W Favoreel
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

2.  A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro.

Authors:  M R Chen; S J Chang; H Huang; J Y Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  A short polypeptide from the herpes simplex virus type 2 ICP10 gene can induce antigen aggregation and autophagosomal degradation for enhanced immune presentation.

Authors:  Xinping Fu; Lihua Tao; Xiaoliu Zhang
Journal:  Hum Gene Ther       Date:  2010-12       Impact factor: 5.695

Review 4.  The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway.

Authors:  Nicholas J Buchkovich; Yongjun Yu; Carisa A Zampieri; James C Alwine
Journal:  Nat Rev Microbiol       Date:  2008-03-03       Impact factor: 60.633

5.  H11/HspB8 and Its Herpes Simplex Virus Type 2 Homologue ICP10PK Share Functions That Regulate Cell Life/Death Decisions and Human Disease.

Authors:  Laure Aurelian; Jennifer M Laing; Ki Seok Lee
Journal:  Autoimmune Dis       Date:  2012-09-27

6.  Oncolytic viruses in the treatment of bladder cancer.

Authors:  Kyle G Potts; Mary M Hitt; Ronald B Moore
Journal:  Adv Urol       Date:  2012-07-29

Review 7.  Review: Oncolytic virotherapy, updates and future directions.

Authors:  Christos Fountzilas; Sukeshi Patel; Devalingam Mahalingam
Journal:  Oncotarget       Date:  2017-05-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.